Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.68 |
| ▸ | KDR | P35968 | 6/20 | 0.68 |
| ▸ | ABL1 | P00519 | 5/20 | 0.68 |
| ▸ | BRAF | P15056 | 4/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.68 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.68 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.68 |
| ▸ | CDK2 | P24941 | 2/20 | 0.68 |
| ▸ | CDK8 | P49336 | 2/20 | 0.68 |
| ▸ | HCK | P08631 | 2/20 | 0.68 |
| ▸ | AXL | P30530 | 2/20 | 0.68 |
| ▸ | FLT3 | P36888 | 2/20 | 0.68 |
| ▸ | MERTK | Q12866 | 2/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.68 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.68 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.68 |
| ▸ | RET | P07949 | 2/20 | 0.68 |
| ▸ | STK25 | O00506 | 1/20 | 0.68 |
| ▸ | CIT | O14578 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762420 | 0.92 | SRC (0.81) | SRCKDRABL1BRAFMAPK14 | |
| SCHEMBL29827937 | 0.92 | CDK2 (0.75) | SRCKDRABL1BRAFMAPK14 | |
| SCHEMBL4941049 | 0.92 | SRC (0.66) | SRCKDRABL1BRAFMAPK14 | |
| SCHEMBL4769220 | 0.92 | CDK2 (0.75) | SRCKDRABL1BRAFMAPK14 | |
| SCHEMBL3166521 | 0.90 | KDR (0.69) | SRCKDRABL1BRAFMAPK14 | |
| SCHEMBL13991087 | 0.90 | KDR (0.70) | SRCKDRABL1BRAFMAPK14 | |
| SCHEMBL4936999 | 0.89 | SRC (0.68) | SRCKDRABL1BRAFMAPK14 | |
| SCHEMBL4763945 | 0.88 | KDR (0.86) | SRCKDRABL1BRAFMAPK14 | |
| SCHEMBL4936158 | 0.88 | KDR (0.70) | SRCKDRABL1BRAFMAPK14 | |
| SCHEMBL4769373 | 0.85 | KDR (0.51) | SRCKDRABL1BRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511730-B1 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-12-10 | — | — | EP | claimed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| EP-1511730-B1 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | disclosed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | SRC 849/4885KDR 3898/4885ABL1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.